Cite
MLA Citation
Morton Coleman et al.. “Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).” Leukemia & lymphoma, vol. 62, no. 2, 2021, pp. 368–376. http://access.bl.uk/ark:/81055/vdc_100122632379.0x000033